95 related articles for article (PubMed ID: 22137623)
21. [Adalimumab].
Aubin F; Barthelemy H
Ann Dermatol Venereol; 2011 Dec; 138(12):842-4. PubMed ID: 22137624
[No Abstract] [Full Text] [Related]
22. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
23. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Reich K; Ortonne JP; Kerkmann U; Wang Y; Saurat JH; Papp K; Langley R; Griffiths CE
Dermatology; 2010; 221(2):172-8. PubMed ID: 20628238
[TBL] [Abstract][Full Text] [Related]
24. Brodalumab (Siliq
Gupta AK; Versteeg SV; Abramovits W; Vincent KD
Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
[No Abstract] [Full Text] [Related]
25. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
[No Abstract] [Full Text] [Related]
26. Clinical experience with infliximab biosimilar in psoriasis.
Ricceri F; Pescitelli L; Lazzeri L; Prignano F
Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
[No Abstract] [Full Text] [Related]
27. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy].
Mahiques Santos L; Martínez Menchón T; Sánchez Carazo JL; Fortea Baixauli JM
Med Clin (Barc); 2005 Jun; 125(4):159. PubMed ID: 15989862
[No Abstract] [Full Text] [Related]
29. Infliximab for the treatment of severe pustular psoriasis.
Elewski BE
J Am Acad Dermatol; 2002 Nov; 47(5):796-7. PubMed ID: 12399781
[No Abstract] [Full Text] [Related]
30. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
[No Abstract] [Full Text] [Related]
31. Infliximab and nephrotic syndrome.
Chin G; Luxton G; Harvey JM
Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
[TBL] [Abstract][Full Text] [Related]
32. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
34. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
35. [Etanercept].
Descamps V
Ann Dermatol Venereol; 2011 Dec; 138(12):845-7. PubMed ID: 22137625
[No Abstract] [Full Text] [Related]
36. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
37. Lentigines in previous psoriatic plaques in a patient treated with infliximab.
Bardazzi F; Magnano M; Antonucci VA; Balestri R; Sgubbi P; Patrizi A
Eur J Dermatol; 2012; 22(5):698-9. PubMed ID: 22940696
[No Abstract] [Full Text] [Related]
38. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
39. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
40. Department of Dermatology was blessed with a wonderful psoriasis specialist. Foreword.
Feldman SR
BioDrugs; 2013 Jan; 27 Suppl 1():1-2. PubMed ID: 23990276
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
